|
1
|
Motzer RJ, Bacik J, Murphy BA, Russo P and
Mazumdar M: Interferon-alfa as a comparative treatment for clinical
trials of new therapies against advanced renal cell carcinoma. J
Clin Oncol. 20:289–296. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Motzer RJ, Hutson TE, Tomczak P, et al:
Overall survival and updated results for sunitinib compared with
interferon alfa in patients with metastatic renal cell carcinoma. J
Clin Oncol. 27:3584–3590. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Motzer RJ, Hudes GR, Curti BD, McDermott
DF, Escudier BJ, Negrier S, et al: Phase I/II trial of temsirolimus
combined with interferon alfa for advanced renal cell carcinoma. J
Clin Oncol. 25:3958–3964. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hudes G, Carducci M, Tomczak P, Dutcher J,
Figlin R, Kapoor A, et al: Global ARCC trial: Temsirolimus,
interferon alfa, or both for advanced renal-cell carcinoma. N Engl
J Med. 356:2271–2281. 2007. View Article : Google Scholar
|
|
5
|
González Larriba JL, Espinosa E, García
Carbonero I, García-Donas J, López M, Meana A, Puente J and
Bellmunt J: Sequential therapy in metastatic renal cell carcinoma:
pre-clinical and clinical rationale for selecting a second- or
subsequent-line therapy with a different mechanism of action.
Cancer Metastasis Rev. 31(Suppl 1): S11–S17. 2012.PubMed/NCBI
|
|
6
|
Atkins MB, Hidalgo M, Stadler WM, Logan
TF, Dutcher JP, Hudes GR, et al: Randomized phase II study of
multiple dose levels of CCI-779, a novel mammalian target of
rapamycin kinase inhibitor, in patients with advanced refractory
renal cell carcinoma. J Clin Oncol. 22:909–918. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gerullis H, Bergmann L, Maute L, Ecke TH,
Eimer C, Bagner JW and Otto T: Feasibility of sequential use of
sunitinib and temsirolimus in advanced renal cell carcinoma. Med
Oncol. 27:373–378. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lamm W, Vogl UM, Bojic M, Zielinski C,
Klingler C, Kramer G and Schmidinger M: Safety and efficacy of
temsirolimus in heavily pretreated patients with metastatic renal
cell carcinoma. Acta Oncol. 51:101–106. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Motzer RJ, Escudier B, Oudard S, Hutson
TE, Porta C, Bracarda S, et al: Efficacy of everolimus in advanced
renal cell carcinoma: a double-blind, randomised,
placebo-controlled phase III trial. Lancet. 372:449–456. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mackenzie MJ, Rini BI, Elson P, Schwandt
A, Wood L, Trinkhaus M, Bjarnason G and Knox J: Temsirolimus in
VEGF-refractory metastatic renal cell carcinoma. Ann Oncol.
22:145–148. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Escudier B, Goupil MG, Massard C and
Fizazi K: Sequential therapy in renal cell carcinoma. Cancer.
115:2321–2326. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hutson TE, Escudier B, Esteban E,
Bjarnason GA, Lim HY, Pittman K, et al: Temsirolimus vs Sorafenib
as Second Line Therapy in Metastatic Renal Cell Carcinoma: Phase 3
Results from the INTORSECT Trial. ESMO: Abstract LBA22,. 2012
|
|
13
|
Rodriguez-Pascual J, Cheng E, Maroto P and
Duran I: Emergent toxicities associated with the use of mTOR
inhibitors in patients with advanced renal carcinoma. Anticancer
Drugs. 21:478–486. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schmidinger M and Bellmunt J: Plethora of
agents, plethora of targets, plethora of side effects in metastatic
renal cell carcinoma. Cancer Treat Rev. 36:416–424. 2010.
View Article : Google Scholar : PubMed/NCBI
|
